Cerity Partners
ONCY

Cerity Partners’s Oncolytics Biotech ONCY Stock Holding History

Cerity Partners’s Portfolio ONCY Stock Details ONCY Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$8.49K Hold
10,000
– – ﹤0.01% 3215
2025
Q4 		$8.74K Hold
10,000
– – ﹤0.01% 2865
2025
Q3 		$14K Hold
10,000
– – ﹤0.01% 2732
2025
Q2 		$7.73K Buy
+10,000
New +$5.3K ﹤0.01% 2623

Other funds holding ONCY

Marshall Wace
Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
SFP
Sandbox Financial Partners Bethesda, Maryland $356M AUM 19.83% 1-Year Est. Return
SI
Seeds Investor New York $735M AUM 17.54% 1-Year Est. Return
TAM
Tocqueville Asset Management New York $6.74B AUM 32.29% 1-Year Est. Return
EFG
Everhart Financial Group Dublin, Ohio $1.56B AUM 34.29% 1-Year Est. Return
XT
XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return
DA
Doliver Advisors Houston, Texas $442M AUM 34.09% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
LPL Financial
LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

Cerity Partners's ONCY Position: Q1 2026 in Review

Cerity Partners held its Oncolytics Biotech (ONCY) position steady in Q1 2026 at 10,000 shares worth $8.49K. The position accounts for ﹤0.01% of the portfolio, ranked #3215.

Cerity Partners first reported a position in ONCY in Q2 2025 and has held it in 4 quarters since. The position peaked at $14K in Q3 2025. 59 funds tracked by Wall St. Rank hold ONCY as of Q1 2026.

  • Cerity Partners held 10,000 shares of Oncolytics Biotech worth $8.49K as of Q1 2026.
  • Cerity Partners left its Oncolytics Biotech share count unchanged in Q1 2026.
  • Oncolytics Biotech made up ﹤0.01% of Cerity Partners's portfolio in Q1 2026, its #3215 holding.
  • Cerity Partners first reported a position in Oncolytics Biotech in Q2 2025 and has held it in 4 quarters since.
  • Cerity Partners's Oncolytics Biotech position peaked at $14K in Q3 2025.
  • 59 funds tracked by Wall St. Rank held Oncolytics Biotech as of Q1 2026.

Based on Cerity Partners's 13F filing for Q1 2026, filed 15 May 2026.